Superworth

Viking Therapeutics revenue VKTX

Sales by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
$0
Latest quarter, Q2 FY26
$0
Fiscal year 2025
$0

Viking Therapeutics' revenue was $0 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$0n/a
FY2024$0n/a
FY2023$0n/a
FY2022$0n/a
FY2021$0n/a
FY2020$0n/a
FY2019$0n/a
FY2018$0n/a
FY2017$0n/a
FY2016$0n/a
FY2015$0n/a
FY2014$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$0n/a$0
Q1 FY26$0n/a$0
Q4 FY25$0n/a$0
Q3 FY25$0n/a$0
Q2 FY25$0n/a$0
Q1 FY25$0n/a$0
Q4 FY24$0n/a$0
Q3 FY24$0n/a$0
Q2 FY24$0n/a$0
Q1 FY24$0n/a$0
Q4 FY23$0n/a$0
Q3 FY23$0n/a$0

Against its peers

Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
VKTXViking Therapeutics$0
NRIXNurix Therapeutics$701.9M
PBHPrestige Consumer Healthcare$1.1B−1% a year
OGNOrganon$6.1B−2% a year
LQDALiquidia$450.9M
HRMYHarmony Biosciences$959.9M+24% a year
ARQTArcutis Biotherapeutics$464M+76% a year
INDVIndivior Pharmaceuticals$1.3B+13% a year
ANIPANI Pharmaceuticals$978.4M+31% a year
PAHCPhibro Animal Health$1.5B+17% a year
ANABAnaptysbion/m
Peer median$978.4M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Viking Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.